Clinical Trials
129
Active:1
Completed:8
Trial Phases
6 Phases
Early Phase 1:3
Phase 1:10
Phase 2:67
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (113 trials with phase data)• Click on a phase to view related trials
Phase 2
67 (59.3%)Not Applicable
19 (16.8%)Phase 3
13 (11.5%)Phase 1
10 (8.8%)Early Phase 1
3 (2.7%)Phase 4
1 (0.9%)Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC
Not Applicable
Not yet recruiting
- Conditions
- Metastatic Colorectal Cancer With Left-sided Primary TumorImmunotherapy
- Interventions
- Drug: FOLFOXIRI + QL1706 + BevacizumabDrug: FOLFOX+QL1706+Cetuximab
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT07070713
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy
Not Applicable
Not yet recruiting
- Conditions
- VunakizumabAdebrelimabSmall Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT07069270
Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)
Not Applicable
Not yet recruiting
- Conditions
- Locally Advanced Cervical Cancer
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT07055399
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
Not Applicable
Not yet recruiting
- Conditions
- Esophagus Cancer
- Interventions
- Procedure: SurgeryDrug: cis-platinumRadiation: Radiation
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT07046221
SLND Versus Non-Dissection Following ESD for T1a Stage Esophageal Squamous Cell Carcinoma
Not Applicable
Not yet recruiting
- Conditions
- Esophageal Cancer
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 102
- Registration Number
- NCT06979986
- Prev
- 1
- 2
- 3
- 4
- 5
- 26
- Next
News
No news found